New hope for KRAS-driven lung cancer: drug duo targets tough mutation

NCT ID NCT07198841

Recruiting now Disease control Sponsor: Guangdong Association of Clinical Trials Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of two drugs (IBI351 and cetuximab β) in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. About 48 participants will receive the treatment to see if it shrinks tumors and how safe it is. The goal is to control the disease, not cure it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER (NON-SMALL CELL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER (NON-SMALL CELL)

Contacts and locations

Locations

Affiliated Tumor Hospital of Guangxi Medical University
NOT_YET_RECRUITING

Nanning, China
Chinese PLA General Hospital
RECRUITING

Beijing, China
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University,
RECRUITING

Guangzhou, Guangdong, 510080, China
The First People's Hospital of Foshan
RECRUITING

Foshan, China
The Fourth Hospital of Hebei Medical University
NOT_YET_RECRUITING

Shijiazhuang, China
The Second Affiliated Hospital of Nanchang University
RECRUITING

Nanchang, China
The first affiliated hospital of nanchang university
RECRUITING

Nanchang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.